Probiodrug AG was a German biotechnology company headquartered in Dresden, Germany, focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2000 as a spin-off from the University of Dresden, Probiodrug specialized in targeting protein post-translational modifications, particularly the conversion of N-terminal glutamine to pyroglutamate (pGlu)[1]. This modification is believed to play a critical role in the aggregation and neurotoxicity of amyloid-beta (Aβ) peptides in Alzheimer's disease.
The company was acquired by Vivoryon Therapeutics in 2019, combining Probiodrug's glutaminyl cyclase (QPCT) inhibitor program with Vivoryon's expertise in precision medicine for age-related diseases[2]. The company's lead compound, varoglutamstat (PQ912), represented one of the most advanced programs targeting pyroglutamate-modified Aβ (pGlu-Aβ) in clinical development.
Probiodrug was established in 2000 as a spin-off company from the Technische Universität Dresden, leveraging research conducted at the university's Institute of Biochemistry. The company's scientific foundation rested on groundbreaking work understanding the role of glutaminyl cyclase (QPCT) in protein post-translational modifications and its implications for neurodegenerative disease.
The founding team, led by Dr. Hans-Urich Demuth, brought expertise in protein biochemistry, enzymology, and drug discovery. Their research had demonstrated that the conversion of N-terminal glutamine residues to pyroglutamate significantly altered the properties of Aβ peptides, making them more aggregation-prone and neurotoxic[3].
The pyroglutamate modification (pGlu) represents a critical post-translational modification that transforms Aβ peptides from relatively benign species into highly toxic aggregates:
Enhanced Aggregation: pGlu-Aβ exhibits dramatically increased aggregation propensity compared to native Aβ1-40/42, forming oligomers and fibrils more rapidly[4]
Increased Neurotoxicity: pGlu-Aβ species demonstrate higher toxicity in neuronal cell cultures and in vivo models
Resistance to Clearance: The pyroglutamate modification renders Aβ more resistant to degradation by proteases and clearance mechanisms
Immunological Evasion: pGlu-Aβ is less recognized by naturally occurring antibodies, limiting immune clearance
Seeding Activity: pGlu-Aβ acts as an efficient "seed" that accelerates the aggregation of wild-type Aβ, promoting plaque formation and spread[4:1]
Varoglutamstat (formerly PQ912) was Probiodrug's lead clinical candidate and represented a first-in-class oral inhibitor of glutaminyl cyclase (QPCT) and glutaminyl cyclase-like protein (QPCTL)[5].
| Property | Details |
|---|---|
| Generic Name | Varoglutamstat |
| Former Code | PQ912 |
| Mechanism | QPCT/QPCTL dual inhibitor |
| Route | Oral |
| Indication | Alzheimer's disease (MCI and early AD) |
| Development Stage | Phase 2 completed |
PQ156 was Probiodrug's second-generation QPCT/QPCTL inhibitor program, designed to build on the learnings from PQ912 with potentially improved pharmacological properties.
| Property | Details |
|---|---|
| Code | PQ156 |
| Mechanism | QPCT/QPCTL dual inhibitor |
| Indication | Alzheimer's disease |
| Development Stage | Preclinical |
Glutaminyl cyclase (QPCT) is a 360-amino acid enzyme that catalyzes the intramolecular cyclization of N-terminal glutamine residues to form pyroglutamate (pGlu) residues[6]. This enzymatic conversion occurs post-translationally and dramatically alters the properties of the modified protein.
In Alzheimer's disease, QPCT catalyzes the conversion of Aβ1-40 and Aβ1-42 to their pyroglutamate-modified forms (pE3-Aβ)[6:1]:
Varoglutamstat works by inhibiting QPCT activity, thereby reducing the formation of pGlu-Aβ species[7]:
Varoglutamstat was evaluated in a first-in-human Phase 1 study in healthy volunteers[8]:
The SHEPHERD study was a Phase 2a clinical trial evaluating varoglutamstat in patients with mild cognitive impairment (MCI) and early Alzheimer's disease[9]:
| Parameter | Details |
|---|---|
| Study Name | SHEPHERD |
| Phase | Phase 2a |
| Patients | MCI and early AD |
| Design | Randomized, double-blind, placebo-controlled |
| Duration | 12 weeks treatment |
| Primary Endpoints | Safety, tolerability, biomarkers |
| Biomarkers | CSF pE3-Aβ, QPCT activity, Aβ species |
The Phase 2 study demonstrated[7:1][10]:
While the primary endpoints focused on safety and biomarker changes, exploratory analyses suggested[11]:
Probiodrug conducted extensive preclinical characterization of varoglutamstat in various Alzheimer's disease models[12][13]:
QPCT knockout mice provided important proof-of-concept[13:1]:
Detailed mechanistic studies demonstrated[14][15]:
In vitro and in vivo studies showed neuroprotective effects[16]:
Probiodrug developed CSF biomarkers to monitor target engagement and disease progression[17][18]:
| Biomarker | Significance |
|---|---|
| pE3-Aβ | Direct marker of QPCT activity and pGlu-Aβ formation |
| QPCT Activity | Enzyme activity in CSF as pharmacodynamic marker |
| Total Aβ | Standard AD biomarker |
| Tau/Phospho-tau | Neurodegeneration markers |
The research demonstrated that QPCT activity and pE3-Aβ in CSF could serve as[17:1]:
Probiodrug's research was published in high-impact peer-reviewed journals, establishing the scientific foundation for QPCT inhibition as an Alzheimer's disease therapeutic strategy:
In 2019, Vivoryon Therapeutics acquired Probiodrug AG, creating a combined company focused on precision medicine approaches to age-related diseases[2:1]:
| Aspect | Details |
|---|---|
| Acquiring Company | Vivoryon Therapeutics AG |
| Target Company | Probiodrug AG |
| Year | 2019 |
| Strategic Rationale | Combined QPCT inhibitor pipeline with Vivoryon's expertise |
Following the acquisition, Vivoryon continued the development of varoglutamstat:
While varogliumstat was the most advanced QPCT inhibitor in development, other programs existed:
| Company | Compound | Status |
|---|---|---|
| Probiodrug/Vivoryon | Varoglutamstat (PQ912) | Phase 2 |
| Merck | Various QPCT inhibitors | Preclinical |
| Pfizer | QPCT antibodies | Research |
Varoglutamstat competed with other amyloid-targeting strategies:
Varoglutamstat's unique positioning included:
Probiodrug's work contributed to validating pGlu-Aβ as a meaningful therapeutic target:
The company's biomarker research advanced AD diagnostics:
Understanding QPCT's normal physiological function provides context for its role in disease. QPCT is involved in the post-translational modification of various peptides and proteins beyond Aβ, including[6:3]:
Neuroendocrine Peptides
Protein Processing
The enzyme's widespread expression in neuroendocrine tissues suggests a normal physiological role in peptide hormone processing. In Alzheimer's disease, this normal function becomes pathological when Aβ serves as an unintended substrate.
Research has revealed variations in pGlu-Aβ across different clinical and pathological subtypes of Alzheimer's disease[3:2][6:4]:
Typical Late-Onset AD
Early-Onset AD
Down Syndrome/Trisomy 21
Mixed Pathology
Recent research has highlighted the role of pGlu-Aβ in the spread of Alzheimer's pathology throughout the brain[4:2][19]:
Seeding Mechanism
Neural Circuit Vulnerability
Therapeutic Implications
Developing a QPCT inhibitor for CNS indications presented several unique challenges[8:1][15:1]:
Brain Penetration
Selectivity
Pharmacokinetics
Varoglutamstat was developed as an oral tablet formulation:
| Formulation Aspect | Details |
|---|---|
| Dosage Form | Film-coated tablet |
| Strength | Various (not publicly disclosed) |
| Dosing | Once or twice daily |
| Food Effects | Studied in clinical trials |
| Stability | Suitable for commercial manufacturing |
Research exploring combination strategies for enhanced efficacy:
With Anti-Amyloid Antibodies
With BACE Inhibitors
With Tau-Targeting Agents
The field continues to advance with newer QPCT inhibitors:
Improved Properties
Dual QPCT/QPCTL Inhibition
Probiodrug's work on glutaminyl cyclase inhibition represented an innovative approach to Alzheimer's disease therapy that specifically targeted the most toxic and aggregation-prone form of amyloid-beta. The company's research established pGlu-Aβ as a validated therapeutic target, demonstrated proof-of-concept for QPCT inhibition, and generated important biomarker data for patient selection and treatment monitoring.
The acquisition by Vivoryon ensured the continuation of this research program, with varoglutamstat advancing through clinical development as one of the few first-in-class mechanisms targeting a specific amyloid-beta species. While the amyloid-targeting field has evolved with the approval of lecanemab and donanemab, QPCT inhibition remains a differentiated approach that could potentially be used in combination with or as an alternative to existing therapies.
The scientific foundation established by Probiodrug—demonstrating the pathological role of pGlu-Aβ, validating QPCT as a therapeutic target, and developing clinical biomarkers—continues to inform Alzheimer's disease research and drug development. The company's work exemplifies how detailed understanding of disease mechanisms at the molecular level can lead to novel therapeutic approaches that address specific pathological species rather than broad target classes.
Vivoryon Acquires Probiodrug. 2019. ↩︎ ↩︎
Pyroglutamate-modified Aβ3-42: A novel target for Alzheimer's disease immunotherapy. 2013. ↩︎ ↩︎ ↩︎
pE3-Aβ acts as a seed for the aggregation of Aβ. 2010. ↩︎ ↩︎ ↩︎
Glutaminyl Cyclase as a Therapeutic Target for Alzheimer's Disease. 2015. ↩︎
Glutaminyl cyclase activity correlates with Aβ pathology in Alzheimer's disease. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
PQ912, a glutaminyl cyclase inhibitor: First results in AD patients. 2018. ↩︎ ↩︎ ↩︎
First-in-human study of PQ912: Safety, pharmacokinetics, and pharmacodynamics. 2017. ↩︎ ↩︎
Safety and tolerability of varoglutamstat in Alzheimer's disease. 2019. ↩︎ ↩︎
Cognitive effects of QPCT inhibition in Alzheimer's models. 2020. ↩︎
Pharmacological characterization of PQ912 in preclinical models. 2019. ↩︎
Glutaminyl cyclase knockout mice: Reduced pE3-Aβ and improved behavior. 2015. ↩︎ ↩︎ ↩︎
Structural basis for glutaminyl cyclase inhibition by small molecules. 2018. ↩︎ ↩︎
Therapeutic targeting of glutaminyl cyclase in neurodegenerative diseases. 2019. ↩︎
Cerebrospinal fluid pE3-Aβ as a biomarker in Alzheimer's disease. 2020. ↩︎ ↩︎
QPCT activity as a biomarker for Alzheimer's disease progression. 2021. ↩︎
Pyroglutamate Aβ: role in neurodegeneration and therapeutic targeting. 2014. ↩︎